Zacks: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus price target of $41.33 for the company and are forecasting that the company will post ($0.47) EPS for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 87 out of 256 based on the ratings given to its competitors.

Several equities research analysts have recently weighed in on OPNT shares. Northland Securities started coverage on Opiant Pharmaceuticals in a research report on Wednesday, May 29th. They set an “outperform” rating and a $42.00 price target on the stock. ValuEngine cut Universal Electronics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 6th.

In related news, insider Phil Skolnick sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $11.71, for a total value of $117,100.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 30,000 shares of company stock worth $362,900. 30.88% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Advisor Group Inc. grew its position in Opiant Pharmaceuticals by 57.2% in the 4th quarter. Advisor Group Inc. now owns 4,700 shares of the technology company’s stock worth $69,000 after purchasing an additional 1,710 shares during the last quarter. BlackRock Inc. grew its position in Opiant Pharmaceuticals by 44.0% in the 4th quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock worth $149,000 after purchasing an additional 3,137 shares during the last quarter. Spark Investment Management LLC grew its position in Opiant Pharmaceuticals by 17.6% in the 1st quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock worth $198,000 after purchasing an additional 2,265 shares during the last quarter. Granite Investment Partners LLC acquired a new stake in shares of Opiant Pharmaceuticals during the 1st quarter valued at about $356,000. Finally, Northern Trust Corp boosted its position in shares of Opiant Pharmaceuticals by 3.5% during the 4th quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after acquiring an additional 1,398 shares in the last quarter. Institutional investors own 20.06% of the company’s stock.

Shares of OPNT traded down $0.15 during midday trading on Friday, hitting $13.10. 13,183 shares of the company traded hands, compared to its average volume of 15,264. The stock’s 50-day moving average is $13.05. Opiant Pharmaceuticals has a one year low of $9.98 and a one year high of $29.55. The firm has a market cap of $51.48 million, a price-to-earnings ratio of -1.85 and a beta of 0.44.

Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings results on Thursday, May 9th. The technology company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.44. Opiant Pharmaceuticals had a negative return on equity of 32.67% and a negative net margin of 30.98%. The firm had revenue of $5.44 million for the quarter, compared to analysts’ expectations of $1.90 million. On average, equities research analysts anticipate that Opiant Pharmaceuticals will post 0.4 EPS for the current year.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Story: Dividend

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.